Bone disease in patients with Gaucher disease

Area of Science:

• Biochemistry
• Genetics
• Metabolic Disorders
• Bone Biology

Background:

• Gaucher disease is an inherited metabolic disorder caused by glucocerebrosidase deficiency.
• This deficiency leads to glucocerebroside accumulation in organs like the liver, spleen, and bone.
• Bone complications include growth abnormalities, osteonecrosis, increased fracture risk, and bone pain.

Purpose of the Study:

• To review the bone manifestations of Gaucher disease.
• To discuss the underlying mechanisms contributing to bone disease.
• To evaluate the impact of current therapies on bone health and fracture risk.

Main Methods:

• Literature review of studies on Gaucher disease and bone involvement.
• Analysis of biochemical, immunological, and coagulation abnormalities.
• Assessment of treatment outcomes, including enzyme replacement and substrate reduction therapies.

Main Results:

• Gaucher disease causes significant bone abnormalities, including impaired remodeling, infarcts, and lesions.
• Abnormal bone metabolism, involving both resorption and formation, is evident.
• Immunological and coagulation factors may contribute to bone disease.
• Enzyme replacement and substrate reduction therapies improve symptoms and radiographic findings.

Conclusions:

• Gaucher disease leads to severe bone complications due to metabolic, immunological, and coagulation dysregulation.
• Current treatments offer symptomatic and radiographic improvements.
• The effect of these therapies on reducing fracture risk in Gaucher disease patients requires further investigation.